Cabometyx was approved in combination with BMY's Opdivo, and Merck supplied Keytruda for an Exelixis study.

1 report, 0 independent Updated Jul 7

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

SpeculativeNo independent reporting found

Who's involved

What this event is mainly about

Exelixis Merck

Keep exploring

Part of

A collaboration between Bristol-Myers Squibb and Exelixis is seeking FDA clearance for an IND application regarding combination therapies. All 1 developments

The entities involved

Exelixis
American biotechnology company

Nothing else this week.
Merck
public company in Indonesia
- Eli Lilly, Novo Nordisk, and Merck are currently competing in the highly competitive GLP-1 obesity market.Sat 17:22
- Merck will share clinical trial results at the American Academy of Ophthalmology (AAO) meeting.Fri 18:13

Related events

The FDA has delayed potential approval of a cancer treatment that utilizes Exelixis in combination with Roche's Tecentriq.Sep 11

Coverage

Newest first; wire copies grouped

Jul 7Unknown outlet